Generic Medicine Info
Indications and Dosage
Adult: 50 mg wkly or 100 mg every 2 wk.

Adult: 150 mg every 12 wk.

Palliative treatment of endometrial and renal carcinoma
Adult: Initially 0.4-1 g wkly. Reduce as necessary, maintenance may be as low as 0.4 g mthly.

Palliative treatment of prostatic carcinoma
Adult: 0.5 g twice wkly for first 3 mth. Maintenance 0.5 g wkly.

Breast cancer
Adult: 0.5-1 g daily for first 4 wk. Maintenance 0.5 g twice wkly.

Palliative treatment of endometrial and renal carcinoma
Adult: 200-600 mg daily.

Mild to moderate endometriosis
Adult: 10 mg tid.

Breast cancer
Adult: 0.4-1.5 g daily. Max: 2 g daily.

Progestogen component in menopausal hormonal replacement therapy
Adult: Dosage dependant on oestrogen component of therapy, several regimens are used: 1.5 mg, 2.5 mg or 5 mg daily; 5 or 10 mg daily for 12-14 days of a 28-day cycle; 20 mg daily for 14 days of a 91-day cycle.

Adult: 2.5-10 mg daily for 5-10 days starting on the 16th-21st day of the menstrual cycle. Repeat for 2 cycles.

Palliative treatment of prostatic carcinoma
Adult: 100-600 mg daily.

Secondary amenorrhoea
Adult: 2.5-10 mg daily for 5-10 days. Repeated for 3 cycles.

Contraception, Endometriosis
Adult: 104 mg every 12-14 wk.
May be taken with or without food. Incidence of minor indigestion may increase as dose increases. Take w/ meals if necessary.
Thromboembolic disorders; cerebral apoplexy; severe hepatic dysfunction; undiagnosed vaginal bleeding, incomplete abortion, hormone-dependent carcinoma; pregnancy.
Special Precautions
Patients with depression, DM, epilepsy, asthma, migraine, hypertension, renal or cardiac dysfunction. Monitor patient closely for loss of vision, proptosis, diplopia and thromboembolic disorders. Lactation.
Adverse Reactions
Depression, fluid retention. Fatigue, insomnia, dizziness, headache, nausea; breast tenderness; wt gain/loss, anorexia; cholestatic jaundice; pain at Inj site.
Potentially Fatal: Thrombophlebitis and pulmonary embolism.
IM/Parenteral/PO/SC: X
Drug Interactions
Aminoglutethimide and enzyme-inducing drugs (e.g. carbamazepine, griseofulvin, phenobarbital, rifampicin, phenytoin) may reduce plasma concentrations leading to reduced efficacy. Additional measures required when medroxyprogesterone is used for contraception during coadministration with these drugs.
Lab Interference
Altered thyroid and liver function tests.
Description: Medroxyprogesterone is a synthetic progestogen which converts the proliferative phase of the endometrium into secretory phase. It has some androgenic and anabolic activities but no oestrogenic effects. Parenteral use leads to inhibition of pituitary gonadotropins, thus preventing follicular maturation and ovulation.
Absorption: Well absorbed from the GIT (oral).
Distribution: Enters the breast milk. Protein-binding: Highly bound to albumin.
Metabolism: Hepatic.
Excretion: Via the urine and faeces (as glucuronide conjugates); Elimination half-life: 24-30 hrs (oral), 50 days (IM).
Disclaimer: This information is independently developed by MIMS based on Medroxyprogesterone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
  • Andalan Injection
  • Depo Progestin
  • Deponeo
  • Planibu
  • Veraplex
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in